Markos Kalligeros
About
Markos Kalligeros is a scholar working on Epidemiology, Infectious Diseases and Neurology.
According to data from OpenAlex, Markos Kalligeros has authored 49 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Epidemiology, 16 papers in Infectious Diseases and 10 papers in Neurology. Recurrent topics in Markos Kalligeros's work include COVID-19 Clinical Research Studies (10 papers), Liver Disease Diagnosis and Treatment (8 papers) and Long-Term Effects of COVID-19 (7 papers). Markos Kalligeros is often cited by papers focused on COVID-19 Clinical Research Studies (10 papers), Liver Disease Diagnosis and Treatment (8 papers) and Long-Term Effects of COVID-19 (7 papers). Markos Kalligeros collaborates with scholars based in United States, Greece and Netherlands. Markos Kalligeros's co-authors include Eleftherios Mylonakis, Fadi Shehadeh, Evangelia K. Mylona, Gregorio Benitez, Philip A. Chan, Curt G. Beckwith, Athanasios Vassilopoulos, Stephanos P. Vassilopoulos, Eleftheria Atalla and Maria Tsikala Vafea and has published in prestigious journals such as Scientific Reports, American Journal of Public Health and The American Journal of Medicine.
In The Last Decade
Markos Kalligeros
48 papers receiving 1.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Markos Kalligeros United States | 16 | 431 | 352 | 227 | 166 | 84 | 49 | 1.0k | ||
| Jingfeng Bi China | 10 | 458 1.1× | 420 1.2× | 164 0.7× | 114 0.7× | 121 1.4× | 22 | 1.0k | ||
| Xiangdong Guan China | 19 | 455 1.1× | 452 1.3× | 246 1.1× | 192 1.2× | 71 0.8× | 84 | 1.6k | ||
| Vijay Gayam United States | 16 | 385 0.9× | 301 0.9× | 166 0.7× | 191 1.2× | 83 1.0× | 127 | 1.3k | ||
| Naresh Bansal India | 13 | 455 1.1× | 477 1.4× | 216 1.0× | 134 0.8× | 109 1.3× | 71 | 1.1k | ||
| Ruiying Zheng China | 10 | 572 1.3× | 221 0.6× | 322 1.4× | 160 1.0× | 18 0.2× | 16 | 1.2k | ||
| Yinlian Wu China | 15 | 649 1.5× | 714 2.0× | 326 1.4× | 248 1.5× | 246 2.9× | 28 | 1.6k | ||
| Ponnudurai Kuperan Singapore | 17 | 325 0.8× | 179 0.5× | 236 1.0× | 74 0.4× | 124 1.5× | 51 | 1.3k | ||
| Vikas Singla India | 16 | 533 1.2× | 638 1.8× | 216 1.0× | 165 1.0× | 143 1.7× | 90 | 1.6k | ||
| Giulio Francesco Romiti Italy | 25 | 216 0.5× | 506 1.4× | 152 0.7× | 70 0.4× | 79 0.9× | 114 | 2.2k | ||
| Perica Davitkov United States | 16 | 381 0.9× | 156 0.4× | 144 0.6× | 369 2.2× | 145 1.7× | 37 | 1.4k |
Countries citing papers authored by Markos Kalligeros
Since
Specialization
Citations
This map shows the geographic impact of Markos Kalligeros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markos Kalligeros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markos Kalligeros more than expected).
Fields of papers citing papers by Markos Kalligeros
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Markos Kalligeros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markos Kalligeros. The network helps show where Markos Kalligeros may publish in the future.
Co-authorship network of co-authors of Markos Kalligeros
This figure shows the co-authorship network connecting the top 25 collaborators of Markos Kalligeros. A scholar is included among the top collaborators of Markos Kalligeros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markos Kalligeros. Markos Kalligeros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Danpanichkul, Pojsakorn, Kwanjit Duangsonk, Markos Kalligeros, et al.. (2025). Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States. Alimentary Pharmacology & Therapeutics. 61(6). 959–970.
2.
Danpanichkul, Pojsakorn, Markos Kalligeros, Pimsiri Sripongpun, et al.. (2024). Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region. Scientific Reports. 14(1).
3.
Vassilopoulos, Athanasios, Markos Kalligeros, Stephanos P. Vassilopoulos, et al.. (2024). Prevalence of Steatotic Liver Disease Among US Adults with Rheumatoid Arthritis. Digestive Diseases and Sciences. 69(3). 989–1003.
4.
Shehadeh, Fadi, Felix LewisOscar, Markos Kalligeros, et al.. (2024). Machine Learning-Assisted High-Throughput Screening for Anti-MRSA Compounds. IEEE/ACM Transactions on Computational Biology and Bioinformatics. 21(6). 1911–1921.
5.
Kalligeros, Markos. (2023). Prevalence and risk factors of nonalcoholic fatty liver disease, high-risk nonalcoholic steatohepatitis, and fibrosis among lean United States adults: NHANES 2017-2020. Annals of Gastroenterology. 36(6). 670–677.
6.
Vassilopoulos, Stephanos P., Athanasios Vassilopoulos, Gregorio Benitez, et al.. (2023). 2509. Association of Non-Alcoholic Fatty Liver Disease with HBV, HAV, and HEV Exposure. Open Forum Infectious Diseases. 10(Supplement_2).
7.
Vassilopoulos, Stephanos P., Markos Kalligeros, Athanasios Vassilopoulos, et al.. (2023). Impact of prior HBV, HAV, and HEV infection on non‐alcoholic fatty liver disease. Journal of Viral Hepatitis. 30(8). 685–693.
8.
Diamantopoulos, Leonidas Nikolaos, Markos Kalligeros, Þorvarður R. Hálfdánarson, Nikolaos Diamantis, & Christos Toumpanakis. (2023). Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies. Biology. 12(8). 1069–1069.
9.
Shehadeh, Fadi, et al.. (2023). Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study. Frontiers in Pharmacology. 14. 1106044–1106044.
10.
Vassilopoulos, Athanasios, Stephanos P. Vassilopoulos, Markos Kalligeros, Fadi Shehadeh, & Eleftherios Mylonakis. (2023). Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: A systematic review and meta-analysis. Frontiers in Medicine. 10. 1110548–1110548.
11.
Kalligeros, Markos, Athanasios Vassilopoulos, Fadi Shehadeh, et al.. (2023). Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 21(7). 1708–1722.
12.
Vassilopoulos, Athanasios, Fadi Shehadeh, Gregorio Benitez, et al.. (2022). The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis. Frontiers in Pharmacology. 13. 992713–992713.
13.
Gil, Raul Macias, et al.. (2021). Characteristics and outcomes of Hispanic/Latinx patients with coronavirus disease 19 (COVID-19) requiring hospitalization in Rhode Island: a retrospective cohort study. Annals of Epidemiology. 58. 64–68.
14.
Desalermos, Athanasios, Michael Pimienta, Markos Kalligeros, et al.. (2021). Safety of Immunizations for the Adult Patient With Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases. 28(9). 1430–1442.
15.
Mylona, Evangelia K., et al.. (2020). The association of obesity with health insurance coverage and demographic characteristics: a statewide cross-sectional study. Medicine. 99(27). e21016–e21016.
16.
Vafea, Maria Tsikala, Eleftheria Atalla, Markos Kalligeros, et al.. (2020). Chest CT findings in asymptomatic cases with COVID-19: a systematic review and meta-analysis. Clinical Radiology. 75(11). 876.e33–876.e39.
17.
Shehadeh, Fadi, Markos Kalligeros, Douglas Shemin, et al.. (2020). Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. Scientific Reports. 10(1). 14332–14332.
18.
Tori, Katerina, Markos Kalligeros, Aman Nanda, et al.. (2020). Association between dementia and psychiatric disorders in long-term care residents. Medicine. 99(31). e21412–e21412.
19.
Diamantopoulos, Leonidas Nikolaos, Faidon‐Marios Laskaratos, Markos Kalligeros, et al.. (2020). Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology. 111(7). 650–659.
20.
Kalligeros, Markos, Fadi Shehadeh, Spyridon Karageorgos, Ioannis M. Zacharioudakis, & Eleftherios Mylonakis. (2019). MRSA colonization and acquisition in the burn unit: A systematic review and meta-analysis. Burns. 45(7). 1528–1536.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jingfeng Bi Breakdown of academic impact, for papers by Xiangdong Guan Breakdown of academic impact, for papers by Vijay Gayam Breakdown of academic impact, for papers by Naresh Bansal Breakdown of academic impact, for papers by Ruiying Zheng Breakdown of academic impact, for papers by Yinlian Wu Breakdown of academic impact, for papers by Ponnudurai Kuperan Breakdown of academic impact, for papers by Vikas Singla Breakdown of academic impact, for papers by Giulio Francesco Romiti Breakdown of academic impact, for papers by Perica Davitkov